Evidence map›Paper›PMID 34602831›Full record

ArticleClinical medicine insights. Circulatory, respiratory and pulmonary medicine2021

Inhaled Nitric Oxide via High-Flow Nasal Cannula in Patients with Acute Respiratory Failure Related to COVID-19.

Abhimanyu Chandel, Saloni Patolia, Kareem Ahmad, Shambhu Aryal, A Whitney Brown, Dhwani Sahjwani, Vikramjit Khangoora, Oksana A Shlobin, Paula C Cameron, Anju Singhal and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical medicine insights. Circulatory, respiratory and pulmonary medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 3 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 3 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Inhaled Nitric Oxide for Clinical Management of COVID-19: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2022
    Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Abhimanyu ChandelWalter Reed National Military Medical Center, Bethesda, MD, USA.ORCID https://orcid.org/0000-0003-4879-1983
Saloni PatoliaVirginia Commonwealth University School of Medicine, Richmond, VA, USA.
Kareem AhmadInova Fairfax Hospital, Falls Church, VA, USA.
Shambhu AryalInova Fairfax Hospital, Falls Church, VA, USA.
A Whitney BrownInova Fairfax Hospital, Falls Church, VA, USA.
Dhwani SahjwaniInova Fairfax Hospital, Falls Church, VA, USA.
Vikramjit KhangooraInova Fairfax Hospital, Falls Church, VA, USA.
Oksana A ShlobinInova Fairfax Hospital, Falls Church, VA, USA.
Paula C CameronInova Fairfax Hospital, Falls Church, VA, USA.
Anju SinghalInova Fairfax Hospital, Falls Church, VA, USA.
Arthur W HoltzclawWalter Reed National Military Medical Center, Bethesda, MD, USA.
Mehul DesaiInova Fairfax Hospital, Falls Church, VA, USA.
Steven D NathanInova Fairfax Hospital, Falls Church, VA, USA.
Christopher S KingInova Fairfax Hospital, Falls Church, VA, USA.
Inova Fairfax Hospital · USWalter Reed National Military Medical Center · USVirginia Commonwealth University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLimited evidence exists regarding use of inhaled nitric oxide (iNO) in spontaneously breathing patients. We evaluated the effectiveness of continuous iNO via high-flow nasal cannula (HFNC) in COVID-19 respiratory failure.

methodsWe performed a multicenter cohort study of patients with respiratory failure from COVID-19 managed with HFNC. Patients were stratified by administration of iNO via HFNC. Regression analysis was used to compare the need for mechanical ventilation and secondary endpoints including hospital mortality, length of stay, acute kidney injury, need for renal replacement therapy, and need for extracorporeal life support.

resultsA total of 272 patients were identified and 66 (24.3%) of these patients received iNO via HFNC for a median of 88 h (interquartile range: 44, 135). After 12 h of iNO, supplemental oxygen requirement was unchanged or increased in 52.7% of patients. Twenty-nine (43.9%) patients treated with iNO compared to 79 (38.3%) patients without iNO therapy required endotracheal intubation (

conclusionIn patients with COVID-19 respiratory failure, iNO delivered via HFNC did not reduce oxygen requirements in the majority of patients or improve clinical outcomes. Given the observed association with increased length of stay, judicious selection of those likely to benefit from this therapy is warranted.

Indexed as

acute respiratory distress syndromeCOVID-19high-flow nasal cannulainhaled nitric oxiderespiratory failure

Identifiers

PMID34602831
PMCPMC8485265
OpenAlexW3204284456

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.